ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
oric pharmaceuticals宣佈展示海報，重點介紹ORIC-114，一種能穿透血腦屏障、口服可用、不可逆的EGFR/HER2抑制劑，用於治療EGFR第20外顯子插入突變和其他非典型突變
ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
oric pharmaceuticals宣佈展示海報，重點介紹ORIC-114，一種能穿透血腦屏障、口服可用、不可逆的EGFR/HER2抑制劑，用於治療EGFR第20外顯子插入突變和其他非典型突變
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間